Nothing Special   »   [go: up one dir, main page]

NO20032801D0 - Tiazolderivater for behandling av PPAR relaterte forstyrrelser - Google Patents

Tiazolderivater for behandling av PPAR relaterte forstyrrelser

Info

Publication number
NO20032801D0
NO20032801D0 NO20032801A NO20032801A NO20032801D0 NO 20032801 D0 NO20032801 D0 NO 20032801D0 NO 20032801 A NO20032801 A NO 20032801A NO 20032801 A NO20032801 A NO 20032801A NO 20032801 D0 NO20032801 D0 NO 20032801D0
Authority
NO
Norway
Prior art keywords
treatment
related disorders
thiazole derivatives
ppar related
ppar
Prior art date
Application number
NO20032801A
Other languages
English (en)
Other versions
NO20032801L (no
Inventor
Rodolfo Cadilla
Iii Millard Hurst Lambert
Romain Luc Marie Gosmini
Michael Lawrence Sierra
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20032801D0 publication Critical patent/NO20032801D0/no
Publication of NO20032801L publication Critical patent/NO20032801L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032801A 2000-12-20 2003-06-19 Tiazolderivater for behandling av PPAR-relaterte forstyrrelser NO20032801L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders

Publications (2)

Publication Number Publication Date
NO20032801D0 true NO20032801D0 (no) 2003-06-19
NO20032801L NO20032801L (no) 2003-08-04

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032801A NO20032801L (no) 2000-12-20 2003-06-19 Tiazolderivater for behandling av PPAR-relaterte forstyrrelser

Country Status (28)

Country Link
EP (1) EP1343773B1 (no)
JP (1) JP4209681B2 (no)
KR (1) KR100815022B1 (no)
CN (1) CN1252057C (no)
AR (1) AR035522A1 (no)
AT (1) ATE344253T1 (no)
AU (1) AU2002246713B2 (no)
BR (1) BR0116370A (no)
CA (1) CA2432188A1 (no)
CY (1) CY1105915T1 (no)
CZ (1) CZ20031737A3 (no)
DE (1) DE60124302T2 (no)
DK (1) DK1343773T3 (no)
ES (1) ES2274914T3 (no)
GB (1) GB0031107D0 (no)
HK (1) HK1059925A1 (no)
HU (1) HUP0400837A3 (no)
IL (2) IL156436A0 (no)
MX (1) MXPA03005699A (no)
MY (1) MY136685A (no)
NO (1) NO20032801L (no)
NZ (1) NZ526543A (no)
PL (1) PL365797A1 (no)
PT (1) PT1343773E (no)
SI (1) SI1343773T1 (no)
TW (1) TWI292759B (no)
WO (1) WO2002062774A1 (no)
ZA (1) ZA200304679B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302397A3 (en) 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
NZ530772A (en) 2001-08-13 2006-03-31 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
ATE369855T1 (de) 2002-02-25 2007-09-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
ATE415160T1 (de) 2002-02-25 2008-12-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2004111020A1 (en) * 2003-06-06 2004-12-23 F. Hoffmann-La Roche Ag Aniline derivatives
JP4627298B2 (ja) 2003-07-02 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー チアゾール環で置換されたインドリル誘導体およびｐｐａｒ調整剤としてのその使用
DE602004022179D1 (de) 2003-09-19 2009-09-03 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1856072A4 (en) * 2005-02-25 2009-10-21 Seoul Nat Univ Ind Foundation THIAZONE DERIVATIVES AS PPAR DELTA LIGANDS AND METHOD FOR THEIR PREPARATION
CN101146784B (zh) * 2005-02-25 2012-09-05 财团法人首尔大学校产学协力财团 作为PPARδ配体的噻唑衍生物及其制造方法
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
JP5455636B2 (ja) * 2006-12-02 2014-03-26 ソウル ナショナル ユニバーシティー インダストリー ファンデーション アリール化合物、その水和物、その溶媒化物、その立体異性体、または、その薬学的に許容される塩、アリール化合物の製造方法、及び、アリール化合物等の用途
RU2444518C2 (ru) 2007-01-08 2012-03-10 Сеул Нэшнл Юниверсити Индастри Фаундейшн ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
EP2260017A1 (en) 2008-03-06 2010-12-15 Amgen, Inc Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
US20120316346A1 (en) * 2010-02-25 2012-12-13 Snu R & Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
WO2002062774A1 (en) 2002-08-15
CA2432188A1 (en) 2002-08-15
NZ526543A (en) 2004-11-26
EP1343773B1 (en) 2006-11-02
PT1343773E (pt) 2007-02-28
KR20030072571A (ko) 2003-09-15
BR0116370A (pt) 2003-12-09
CY1105915T1 (el) 2011-04-06
AU2002246713B2 (en) 2004-09-09
JP4209681B2 (ja) 2009-01-14
TWI292759B (en) 2008-01-21
CN1527822A (zh) 2004-09-08
CN1252057C (zh) 2006-04-19
IL156436A (en) 2008-06-05
MY136685A (en) 2008-11-28
ATE344253T1 (de) 2006-11-15
IL156436A0 (en) 2004-01-04
SI1343773T1 (sl) 2007-04-30
GB0031107D0 (en) 2001-01-31
ZA200304679B (en) 2004-10-04
ES2274914T3 (es) 2007-06-01
HUP0400837A3 (en) 2007-11-28
DE60124302T2 (de) 2007-05-03
EP1343773A1 (en) 2003-09-17
JP2004518702A (ja) 2004-06-24
HK1059925A1 (en) 2004-07-23
PL365797A1 (en) 2005-01-10
KR100815022B1 (ko) 2008-03-18
HUP0400837A2 (hu) 2004-08-30
DE60124302D1 (de) 2006-12-14
CZ20031737A3 (cs) 2003-10-15
MXPA03005699A (es) 2003-10-06
DK1343773T3 (da) 2007-02-05
NO20032801L (no) 2003-08-04
AR035522A1 (es) 2004-06-02

Similar Documents

Publication Publication Date Title
NO20032801D0 (no) Tiazolderivater for behandling av PPAR relaterte forstyrrelser
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
NO20024273L (no) Terapeutiske anvendelser av PPAR-mediatorer
NO20031626L (no) Pyridonderivater for behandling av atherosklerose
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20033682L (no) Epothilone-derivater for behandling av refraktor-tumorer
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20023803D0 (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
NO20026005L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO20030717D0 (no) Forbindelser for behandling av avhengighetsforstyrrelser
NO20005216D0 (no) Sammensetning for behandling av eksterne sekresjonssykdommer unntatt hypolakrimasjon
NO20030127L (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
NO20026029L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20026028D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application